Patent US2632921A successfully refreshed from Google Patents.
Patent US5389670A successfully refreshed from Google Patents.
US5389670A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Methods of inhibiting the symptoms of premenstrual syndrome/late luteal phase dysphoric disorder
Assignee: Eli Lilly and Co
•
Filing: 1993-12-21
•
Granted: 1995-02-14
•
Expires: 2013-12-21
Abstract
Abstract A method of inhibiting one or more symptom of premenstrual syndrome/late luteal phase dysphoric disorder comprising administering to a female human in need of treatment an effective amount of a compound having the formula ##STR1## wherein R 1 and R 3 are independently hydrogen, --CH 3 , --CO--(C 1 -C 6 alkyl), or --CO--Ar, in which Ar is optionally substituted phenyl; R 2 is selected from the group consisting of pyrrolidino, hexamethyleneimino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.
Inventors
- 👤 Steven A. Fontana
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 13:58
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/435; A61K31/44; A61K31/445; A61K31/4523; A61K31/4535; A61K31/40; A61K31/4025; A61K31/55; A61P; A61P13/00; A61P13/02; A61P15/00; A61P25/00; A61P25/04; A61P25/20; A61P5/00; A61P5/24; A61P5/28; A61P5/32; C; C07; C07D; C07D409/00; C07D409/02; C07D409/10
Claims Analysis
Total Claims: 4
Claim 1
Independent Claim
82 words
A method of inhibiting one or more symptom of premenstrual syndrome/late luteal phase dysphoric disorder comprising administering to a female human in need of treatment an effective amount of a compound having the formula ##STR3## wherein R 1 and R 3 are independently hydrogen, --CH 3 , --CO--(C 1 -C 6 alkyl), or --CO--Ar, in which Ar is optionally substituted phenyl; R 2 is selected from the group consisting of pyrrolidine, hexamethyleneimino, and piperidino; or a pharmaceutically acceptable salt or solvate thereof.
Claim 2
Independent Claim
82 words
A method of inhibiting one or more symptom of premenstrual syndrome/late luteal phase dysphoric disorder comprising administering to a female human in need of treatment an effective amount of a compound having the formula ##STR3## wherein R 1 and R 3 are independently hydrogen, --CH 3 , --CO--(C 1 -C 6 alkyl), or --CO--Ar, in which Ar is optionally substituted phenyl; R 2 is selected from the group consisting of pyrrolidine, hexamethyleneimino, and piperidino; or a pharmaceutically acceptable salt or solvate thereof.
Claim 3
Dependent Claim
13 words
The method of claim 1 wherein said compound is the hydrochloride salt thereof.
Claim 4
Dependent Claim
14 words
The method of claim 1 wherein said compound is ##STR4## or its hydrochloride salt.
References Cited (Backward Citations)
US4133814A
Cited
US4380635A
Cited
US4418068A
Cited
US5075321A
Cited
WO1993010113A1
Cited
WO1993010741A2
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1998-02-13 | 1998-08-15 | 1999-02-14 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2002-02-13 | 2002-08-15 | 2003-02-14 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2006-02-13 | 2006-08-15 | 2007-02-14 | $7700.00 | Window Closed / Lapsed |